Lista de obras - Enrico Derenzini - Dominio Público Uruguay

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

artículo científico publicado en 2008

A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma

scientific article published on 13 September 2011

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

artículo científico publicado en 2008

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

artículo científico publicado en 2011

Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases

artículo científico publicado en 2013

Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients

artículo científico publicado en 2012

Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.

artículo científico publicado en 2009

Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin

artículo científico publicado en 2013

Bendamustine: role and evidence in lymphoma therapy, an overview

artículo científico

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

artículo científico publicado en 2012

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

artículo científico publicado en 2013

Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma

artículo científico publicado en 2007

CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission

artículo científico publicado en 2009

Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.

artículo científico publicado en 2013

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

artículo científico publicado en 2011

Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports

artículo científico publicado en 2013

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma

artículo científico publicado en 2009

Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge

scientific article published on 01 January 2008

Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens

artículo científico publicado en 2012

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study

artículo científico publicado en 2010

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

artículo científico publicado en 2008

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

artículo científico publicado en 2009

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

article

Hairy cell leukemia: evaluation of the long-term outcome in 121 patients

artículo científico publicado en 2010

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience

artículo científico publicado en 2015

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

artículo científico publicado en 2015

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

scientific article published on 19 April 2011

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

artículo científico publicado en 2012

Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.

artículo científico publicado en 2013

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.

artículo científico publicado en 2009

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma

artículo científico publicado en 2010

Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series.

artículo científico

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

artículo científico publicado en 2007

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

artículo científico publicado en 2010

Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease

artículo científico publicado en 2011

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

scientific article published on 28 April 2011

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

artículo científico publicado en 2008

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients

scientific article published on 07 May 2011

Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.

artículo científico publicado en 2014

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

artículo científico publicado en 2009

Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remi

scientific article published on 18 April 2014

Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

article

Slow evolution of liver metastasis from colon cancer.

artículo científico publicado en 2005

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

artículo científico publicado en 2009

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

artículo científico publicado en 2013

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.

artículo científico publicado en 2011

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

artículo científico publicado en 2011

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.

artículo científico publicado en 2012

Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.

artículo científico publicado en 2018

Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.

artículo científico publicado en 2006

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

artículo científico publicado en 2007

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome

scientific article published on 01 August 2010

Lista de obras de Enrico Derenzini

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma

A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma

Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases

Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients

Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience.

Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin

Bendamustine: role and evidence in lymphoma therapy, an overview

Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma

CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission

Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma.

Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial

Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports

Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma

Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: A diagnostic and therapeutic challenge

Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study

Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma

Hairy cell leukemia: evaluation of the long-term outcome in 121 patients

High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified

Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).

Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.

MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients.

Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma

Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series.

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients

Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease

Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances

Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma

Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients

Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma.

Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma

Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remi

Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin

Slow evolution of liver metastasis from colon cancer.

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.

The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.

The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.

Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.

Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.

VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly

Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome